Behavior of solubilized collagen as a bioimplant

Knapp, Terry R.; Luck, Edward E.; Daniels, John R.

doi:10.1016/0022-4804(77)90196-2

Cited by 108 publications

(36 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The first commercially successful, FDA-approved injectable filler for soft tissue augmentation was a solution of soluble collagen [1, 2] marketed by Collagen Corporation in 1983. Until then, the only widely used “off-the-shelf” injectable filler had been liquid dimethylpolysiloxane (silicone).…”

mentioning

confidence: 99%

ArteFill® Permanent Injectable for Soft Tissue Augmentation: I. Mechanism of Action and Injection Techniques

Knapp²,

et al. 2009

Self Cite

View full text Add to dashboard Cite

After more than 25 years of research and development, in October 2006 ArteFill® became the first and only permanent injectable wrinkle filler to receive FDA approval. ArteFill is a third-generation polymeric microsphere-based filler, following its predecessor Artecoll®, which was marketed outside the United States between 1994 and 2006. ArteFill is approved for the correction of nasolabial folds and has been used in over 15,000 patients since its U.S. market introduction in February 2007. No serious side effects have been reported to date according to the FDA’s MAUDE reporting database. ArteFill consists of polymethylmethacrylate (PMMA) microspheres (20% by volume), 30–50 μm in diameter, suspended in 3.5% bovine collagen solution (80% by volume) and 0.3% lidocaine. The collagen carrier is absorbed within 1 month after injection and completely replaced by the patient’s own connective tissue within 3 months. Each cc of ArteFill contains approximately six million microspheres and histological studies have shown that long-term wrinkle correction consists of 80% of the patient’s own connective tissue and 20% microspheres. The standard injection technique is subdermal tunneling that delivers a strand of ArteFill at the dermal–subdermal junction. This strand beneath a wrinkle or fold acts like a support structure that protects against further wrinkling and allows the diminished thickness of the dermis to recover to its original thickness.

show abstract

mentioning

confidence: 99%

ArteFill® Permanent Injectable for Soft Tissue Augmentation: I. Mechanism of Action and Injection Techniques

Knapp²,

et al. 2009

Self Cite

View full text Add to dashboard Cite

show abstract

“…This significant loss of volume is probably attributable to degradation by macrophages and precipitation of collagen fibers at body temperature. 40 Some previous authors have reported ingrowth of connective tissue into collagen implants and collagen neoformation, 37 whereas others have not. 10 In the present study, we did not detect collagen neoformation within Zyderm 1 implants.…”

Section: Plastic and Reconstructive Surgery • October 2007mentioning

confidence: 99%

Biocompatibility of Agarose Gel as a Dermal Filler: Histologic Evaluation of Subcutaneous Implants

Fernández-Cossío

León-Mateos

Sampedro

et al. 2007

Plastic and Reconstructive Surgery

View full text Add to dashboard Cite

show abstract

“…Zyderm I, introduced in 1977 (Knapp et al 1977) and FDA approved in 1981, is an injectable soluble, bovine collagen implant for the treatment of fine, superficial lines. The acid-soluble collagen is extracted from bovine dermal tissue with acetic-acid and is then pepsin-treated to yield telopeptide-poor collagen with low antigenicity.…”

Section: Bovine Collagenmentioning

confidence: 99%

“…The collagen is 96% type I and 4% type III collagen and it is purified to over 99% and dispersed in phosphate buffered saline (PBS) containing 0.3% lidocaine hydrochloride to a concentration of 35 mg/ml. The monomeric collagen solution spontaneously polymerises at 37 °C (Knapp, Luck, & Daniels 1977). Zyderm II, FDA approved in 1983, is similar to Zyderm I but contains 65 mg/ml of collagen and is used to treat mild to moderate lines.…”

Section: Bovine Collagenmentioning

confidence: 99%